Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting

On March 14, 2023 Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, reported that four abstracts, including a late-breaking abstract, highlighting preclinical data from both the hypoimmune and fusogen platforms have been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place April 14-19, 2023 in Orlando, FL (Press release, Sana Biotechnology, MAR 14, 2023, View Source [SID1234628660]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Late-breaking poster details:

Title: Increased potency of CD8-targeted fusosomes enhances CAR gene delivery to resting primary T cells
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 3
Session Date: Wednesday, April 19, 2023
Session Time: 9:00 a.m. – 12:30 p.m. ET
Location: Poster Section 35
Abstract Number: LB311

Poster details:

Title: Modulation of resting T cell status to enhance transduction and CAR T expansion following exposure to CD8-targeted fusosomes
Session Category: Experimental and Molecular Therapeutics
Session Title: Gene and Vector-based Therapy
Session Date: Monday, April 17, 2023
Session Time: 1:30 p.m. – 5:00 p.m. ET
Location: Poster Section 16
Abstract Number: 2734

Title: Development of a novel, fully human anti-CD19 chimeric antigen receptor for in vivo delivery via CD8-targeted fusosome
Session Category: Experimental and Molecular Therapeutics
Session Title: Gene and Vector-based Therapy
Session Date: Monday, April 17, 2023
Session Time: 1:30 p.m. – 5:00 p.m. ET
Location: Poster Section 16
Abstract Number: 2735

Title: Engineered hypoimmune CAR T cells provide lasting tumor control in immunocompetent allogeneic humanized mice even with re-challenge
Session Category: Immunology
Session Title: CAR T-cell Therapy 2
Session Date: Tuesday, April 18, 2023
Session Time: 9:00 a.m. – 12:30 p.m. ET
Location: Poster Section 23
Abstract Number: 4091

Full regular abstracts and late-breaking abstract titles are available for viewing via the AACR (Free AACR Whitepaper) Online Itinerary Planner located here: View Source!/10828. Late-breaking abstract text will be posted to the AACR (Free AACR Whitepaper) Online Itinerary Planner and Meeting App on Friday, April 14, 2023 at 12:00 p.m. ET.